Cargando…
The Quandary of DNA-Based Treatment Assessment in De Novo Metastatic Prostate Cancer in the Era of Precision Oncology
Guidelines for genetic testing have been established for multiple tumor types, frequently indicating the most confident molecularly targeted treatment options. However, considering the often-complex presentation of individual cancer patients, in addition to the combinatorial complexity and inherent...
Autores principales: | Nakken, Sigve, Lilleby, Wolfgang, Switlyk, Marta D., Knudsen, Karen E., Lilleby, Oscar, Zhao, Sen, Kaveh, Fatemeh, Ekstrøm, Per O., Urbanucci, Alfonso, Hovig, Eivind |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8143497/ https://www.ncbi.nlm.nih.gov/pubmed/33922147 http://dx.doi.org/10.3390/jpm11050330 |
Ejemplares similares
-
Personal Cancer Genome Reporter: variant interpretation report for precision oncology
por: Nakken, Sigve, et al.
Publicado: (2018) -
Automated amplicon design suitable for analysis of DNA variants by melting techniques
por: Ekstrøm, Per Olaf, et al.
Publicado: (2015) -
Translocational renal cell carcinoma (t(6;11)(p21;q12) with transcription factor EB (TFEB) amplification and an integrated precision approach: a case report
por: Lilleby, Wolfgang, et al.
Publicado: (2015) -
Restart of androgen deprivation therapy after goserelin induced pituitary apoplexy in a patient with disseminated prostate cancer a case report and five-years follow-up
por: Aljabri, Belal, et al.
Publicado: (2021) -
Metastatic-directed therapy using PSMA-PET/CT at PSA relapse
por: Lilleby, Oscar, et al.
Publicado: (2019)